ARCHIVES

Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

SPORE Eligibility, Cost Issues Clarified In Addendum To RFA

October 25, 1991

NSABP Disputed NCI Cost Estimate For P-4 Trial.

May 25, 2007

NCAB Committee Approves NCI Plans For Organ Systems

February 5, 1988

Hatfield, Kennedy Bill would Establish Panel for Clinical Research

February 16, 1996

Cost of Care: Medicare Patients Charged More In Outpatient Care Settings

November 1, 2013

In Brief: Rall Says He’ll Return Money To NCI If There Isn’t Any Left; OMB Releases 28 Positions For NTP

February 1, 1980